Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The insulinotropic properties of zebrafish GIP (zfGIP) were assessed in vitro using clonal pancreatic β-cell lines and isolated mouse islets and acute effects on glucose tolerance and insulin release in vivo were evaluated in mice. The peptide produced a dose-dependent increase in the rate of insulin release from BRIN-BD11 rat clonal β-cells at concentrations ≥30nM. Insulin release from 1.1 B4 human clonal β-cells and mouse islets was significantly increased by zfGIP (10nM and 1μM). The in vitro insulinotropic activity of zfGIP was decreased after incubating BRIN-BD11 cells with the GLP-1 receptor antagonist, exendin-4(9-39) (p
LanguageEnglish
Pages182-189
JournalPeptides
Volume100
Early online date20 Nov 2017
DOIs
Publication statusE-pub ahead of print - 20 Nov 2017

Fingerprint

Zebrafish
Insulin
Glucose
Insulin-Secreting Cells
Islets of Langerhans
Rats
Cells
Cell Line
Peptides
Glucagon-Like Peptide-1 Receptor
In Vitro Techniques

Keywords

  • Type 2 diabetes
  • Zebrafish
  • GIP
  • GLP-1
  • Glucagon
  • Evolution

Cite this

@article{ce44b50d68bf4471b8e875b5fe37b5ed,
title = "Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.",
abstract = "The insulinotropic properties of zebrafish GIP (zfGIP) were assessed in vitro using clonal pancreatic β-cell lines and isolated mouse islets and acute effects on glucose tolerance and insulin release in vivo were evaluated in mice. The peptide produced a dose-dependent increase in the rate of insulin release from BRIN-BD11 rat clonal β-cells at concentrations ≥30nM. Insulin release from 1.1 B4 human clonal β-cells and mouse islets was significantly increased by zfGIP (10nM and 1μM). The in vitro insulinotropic activity of zfGIP was decreased after incubating BRIN-BD11 cells with the GLP-1 receptor antagonist, exendin-4(9-39) (p",
keywords = "Type 2 diabetes, Zebrafish, GIP, GLP-1, Glucagon, Evolution",
author = "GV Graham and JM Conlon and YHA Abdel-Wahab and Gault, {Victor A} and Peter Flatt",
year = "2017",
month = "11",
day = "20",
doi = "10.1016/j.peptides.2017.11.007",
language = "English",
volume = "100",
pages = "182--189",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier",

}

TY - JOUR

T1 - Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.

AU - Graham, GV

AU - Conlon, JM

AU - Abdel-Wahab, YHA

AU - Gault, Victor A

AU - Flatt, Peter

PY - 2017/11/20

Y1 - 2017/11/20

N2 - The insulinotropic properties of zebrafish GIP (zfGIP) were assessed in vitro using clonal pancreatic β-cell lines and isolated mouse islets and acute effects on glucose tolerance and insulin release in vivo were evaluated in mice. The peptide produced a dose-dependent increase in the rate of insulin release from BRIN-BD11 rat clonal β-cells at concentrations ≥30nM. Insulin release from 1.1 B4 human clonal β-cells and mouse islets was significantly increased by zfGIP (10nM and 1μM). The in vitro insulinotropic activity of zfGIP was decreased after incubating BRIN-BD11 cells with the GLP-1 receptor antagonist, exendin-4(9-39) (p

AB - The insulinotropic properties of zebrafish GIP (zfGIP) were assessed in vitro using clonal pancreatic β-cell lines and isolated mouse islets and acute effects on glucose tolerance and insulin release in vivo were evaluated in mice. The peptide produced a dose-dependent increase in the rate of insulin release from BRIN-BD11 rat clonal β-cells at concentrations ≥30nM. Insulin release from 1.1 B4 human clonal β-cells and mouse islets was significantly increased by zfGIP (10nM and 1μM). The in vitro insulinotropic activity of zfGIP was decreased after incubating BRIN-BD11 cells with the GLP-1 receptor antagonist, exendin-4(9-39) (p

KW - Type 2 diabetes

KW - Zebrafish

KW - GIP

KW - GLP-1

KW - Glucagon

KW - Evolution

U2 - 10.1016/j.peptides.2017.11.007

DO - 10.1016/j.peptides.2017.11.007

M3 - Article

VL - 100

SP - 182

EP - 189

JO - Peptides

T2 - Peptides

JF - Peptides

SN - 0196-9781

ER -